Oncotelic <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Private Placement of Convertible Notes and Warrants
Oncotelic Therapeutics Inc. has announced the completion of subscription agreements with certain accredited investors for a private placement, issuing a total of 11 units as part of an offering of up to 500 units. Each unit consists of a $25,000 note bearing 12% annual interest, convertible into either 250,000 shares of Oncotelic's common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc., a subsidiary, at $1.00 per share. The units also include warrants to purchase additional shares of Oncotelic or EdgePoint. The securities were sold in reliance on exemptions from registration under the Securities Act of 1933 and are not registered for public sale. Existing investors in a prior 2023 note offering were also able to exchange their notes for new units and convert EdgePoint shares into Oncotelic shares at a specified rate. The company also entered into a Registration Rights Agreement in connection with the offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-026883), on December 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.